Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 52,822 shares of the pharmaceutical company's stock after selling 3,413 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Vertex Pharmaceuticals were worth $25,609,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in VRTX. Aries Wealth Management acquired a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $293,000. Polar Asset Management Partners Inc. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $22,954,000. Brighton Jones LLC increased its holdings in shares of Vertex Pharmaceuticals by 45.0% during the first quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock valued at $3,113,000 after acquiring an additional 1,994 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Vertex Pharmaceuticals by 25.1% during the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock valued at $2,425,000 after acquiring an additional 1,005 shares in the last quarter. Finally, APG Asset Management N.V. increased its holdings in shares of Vertex Pharmaceuticals by 189.7% during the fourth quarter. APG Asset Management N.V. now owns 359,285 shares of the pharmaceutical company's stock valued at $139,724,000 after acquiring an additional 235,265 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded up $5.35 during midday trading on Wednesday, reaching $469.55. 785,364 shares of the company's stock traded hands, compared to its average volume of 1,424,397. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a market cap of $120.58 billion, a P/E ratio of -119.78 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The company has a fifty day simple moving average of $447.43 and a two-hundred day simple moving average of $461.58.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. During the same quarter last year, the business earned $4.76 EPS. The company's quarterly revenue was up 2.6% on a year-over-year basis. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on VRTX shares. Scotiabank cut their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a report on Tuesday, May 6th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Finally, Wolfe Research downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a report on Wednesday, May 7th. Fourteen analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $511.71.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.